JP7592064B2 - Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法 - Google Patents

Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法 Download PDF

Info

Publication number
JP7592064B2
JP7592064B2 JP2022502423A JP2022502423A JP7592064B2 JP 7592064 B2 JP7592064 B2 JP 7592064B2 JP 2022502423 A JP2022502423 A JP 2022502423A JP 2022502423 A JP2022502423 A JP 2022502423A JP 7592064 B2 JP7592064 B2 JP 7592064B2
Authority
JP
Japan
Prior art keywords
antibody
asthma
antigen
subject
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541191A (ja
JP2022541191A5 (enExample
Inventor
ヘリベルト・シュタウディンガー
アリエール・テパー
ニキル・アミン
シヴァン・ハレル
ニール・グラハム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022541191A publication Critical patent/JP2022541191A/ja
Publication of JP2022541191A5 publication Critical patent/JP2022541191A5/ja
Priority to JP2024201235A priority Critical patent/JP2025026945A/ja
Application granted granted Critical
Publication of JP7592064B2 publication Critical patent/JP7592064B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022502423A 2019-07-16 2020-07-15 Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法 Active JP7592064B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024201235A JP2025026945A (ja) 2019-07-16 2024-11-19 Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962874747P 2019-07-16 2019-07-16
US62/874,747 2019-07-16
US201962877031P 2019-07-22 2019-07-22
US62/877,031 2019-07-22
US202063004084P 2020-04-02 2020-04-02
US63/004,084 2020-04-02
EP20315237 2020-05-07
EP20315237.6 2020-05-07
PCT/US2020/042075 WO2021011614A1 (en) 2019-07-16 2020-07-15 Methods for treating or preventing asthma by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024201235A Division JP2025026945A (ja) 2019-07-16 2024-11-19 Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Publications (3)

Publication Number Publication Date
JP2022541191A JP2022541191A (ja) 2022-09-22
JP2022541191A5 JP2022541191A5 (enExample) 2023-07-24
JP7592064B2 true JP7592064B2 (ja) 2024-11-29

Family

ID=71899976

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502423A Active JP7592064B2 (ja) 2019-07-16 2020-07-15 Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
JP2024201235A Pending JP2025026945A (ja) 2019-07-16 2024-11-19 Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024201235A Pending JP2025026945A (ja) 2019-07-16 2024-11-19 Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法

Country Status (11)

Country Link
US (2) US12398212B2 (enExample)
EP (1) EP3999114A1 (enExample)
JP (2) JP7592064B2 (enExample)
KR (1) KR20220034878A (enExample)
CN (1) CN115175700B (enExample)
AU (1) AU2020315369A1 (enExample)
BR (1) BR112022000740A2 (enExample)
CA (1) CA3147436A1 (enExample)
IL (1) IL289731A (enExample)
MX (1) MX2022000649A (enExample)
WO (1) WO2021011614A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
EP4081544A1 (en) * 2019-12-23 2022-11-02 Sanofi Biotechnology Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
US20260098100A1 (en) * 2024-10-04 2026-04-09 Prana Therapies, Inc. Il-4r and tslp inhibitors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527364A (ja) 2012-08-21 2015-09-17 サノフイ Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH06510750A (ja) 1991-05-03 1994-12-01 セラジェン　インク 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
ATE326239T1 (de) 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US20020002132A1 (en) 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1304115B1 (en) 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60203652T2 (de) 2001-01-31 2005-09-08 Pfizer Products Inc., Groton Nikotinsäureamid-Derivate und ihre Mimetika als Inhibitoren von PDE4-Isozyme
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20050031609A1 (en) 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
AR037456A1 (es) 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2004070011A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
WO2005032399A2 (en) 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20100144646A1 (en) 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US20090062168A1 (en) 2007-08-27 2009-03-05 Joseph Timar Process for making a two-cycle gasoline engine lubricant
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009061819A1 (en) 2007-11-05 2009-05-14 The Regents Of The University Of Colorado Minimally-invasive measurement of esophageal inflammation
KR101759457B1 (ko) 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009121847A2 (en) 2008-04-02 2009-10-08 Apogenix Gmbh Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
AU2009322556A1 (en) 2008-12-01 2011-07-21 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN107320722A (zh) 2009-09-07 2017-11-07 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
JP5167552B2 (ja) 2010-03-16 2013-03-21 エアソネット・アクチボラゲット 温度制御された層状空気流治療法による、喘息およびアレルギー性鼻炎の治療、ならびに睡眠の質の改善
WO2011156000A2 (en) 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
EP3970726A1 (en) 2010-06-24 2022-03-23 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
US8826693B2 (en) 2010-08-30 2014-09-09 Corning Incorporated Apparatus and method for heat treating a glass substrate
UA111731C2 (uk) 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012049278A1 (en) 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
EP2677838B1 (en) 2012-06-18 2017-12-06 Whirlpool Corporation Microwave heating apparatus
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
CN103674979B (zh) 2012-09-19 2016-12-21 同方威视技术股份有限公司 一种行李物品ct安检系统及其探测器装置
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
EP3624820A1 (en) 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Use of klk5 antagonists for treatment of a disease
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) * 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CN112513293A (zh) 2018-05-22 2021-03-16 阿尔卡贝洛股份公司 通过免疫治疗来治疗特应性疾病的生物标志物方法
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
BR112021012647A2 (pt) 2018-12-27 2021-09-14 Akeso Biopharma, Inc Anticorpo, polipeptídeo isolado, polinucleotídeo isolado, vetor, célula hospedeira, métodos para preparar o anticorpo e para a prevenção e/ou tratamento e/ou tratamento adjuvante e/ou diagnóstico de uma doença, conjugado de anticorpo, anticorpo multiespecífico, proteína de fusão, composição farmacêutica, kit, usos do anticorpo, método in vivo ou in vitro, célula de hibridoma e anticorpo monoclonal
US20210000949A1 (en) 2019-05-01 2021-01-07 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
EP4081544A1 (en) 2019-12-23 2022-11-02 Sanofi Biotechnology Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
JP2023544406A (ja) 2020-10-05 2023-10-23 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法
IL310362A (en) 2021-07-26 2024-03-01 Sanofi Biotechnology Methods for the treatment of chronic spontaneous urticaria by administration of an IL-4R antagonist
IL312187A (en) 2021-10-20 2024-06-01 Regeneron Pharma Methods for treating prurigo nodularis by administering an IL-4R antagonist
AU2024241290A1 (en) 2023-03-22 2025-11-06 Regeneron Pharmaceuticals, Inc. Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527364A (ja) 2012-08-21 2015-09-17 サノフイ Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Clinic Rev Allerg Immunol，2016年，Vol.50，pp.252-272
N Engl J Med.，2013年，Vol.368, No.26，pp.2455-2466
N Engl J Med.，2018年，Vol.378, No.26，pp.2486-2496
Respir Med case Rep，Vol.28，2019年06月，100875

Also Published As

Publication number Publication date
CA3147436A1 (en) 2021-01-21
CN115175700A (zh) 2022-10-11
CN115175700B (zh) 2026-04-03
AU2020315369A1 (en) 2022-03-03
JP2025026945A (ja) 2025-02-26
BR112022000740A2 (pt) 2022-07-05
US20210032354A1 (en) 2021-02-04
US12398212B2 (en) 2025-08-26
JP2022541191A (ja) 2022-09-22
WO2021011614A1 (en) 2021-01-21
KR20220034878A (ko) 2022-03-18
MX2022000649A (es) 2022-06-08
US20260049150A1 (en) 2026-02-19
EP3999114A1 (en) 2022-05-25
IL289731A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
JP7695298B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP7609901B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JP7592064B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
US20220169739A1 (en) Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
TWI894144B (zh) 藉由投予il-33拮抗劑治療或預防哮喘之方法
JP2026068738A (ja) Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
RU2832774C2 (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
RU2855851C1 (ru) Способы лечения астмы у субъектов-детей путем введения антагониста il-4r
JP7216157B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
IL301777A (en) Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CN116848138A (zh) 通过施用il-4r拮抗剂治疗儿科受试者的哮喘的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241119

R150 Certificate of patent or registration of utility model

Ref document number: 7592064

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150